Patents by Inventor Matityahu Fridkin

Matityahu Fridkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10072044
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Grant
    Filed: June 12, 2016
    Date of Patent: September 11, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Schwartz-Eisenbach, Matityahu Fridkin, Michal Cardon-Yaakov
  • Patent number: 9956295
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: May 1, 2018
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
  • Publication number: 20170247429
    Abstract: The present invention relates to blood-brain barrier disrupting agents containing a modified serum albumin comprising serum albumin. The present invention further relates to pharmaceutical compositions comprising said agents and use thereof for the treatment of brain diseases and disorders.
    Type: Application
    Filed: September 16, 2015
    Publication date: August 31, 2017
    Inventors: Itzik Cooper, David Guez, David Last, Yoram Shechter, Matityahu Fridkin, Yael Mardor
  • Publication number: 20170119847
    Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.
    Type: Application
    Filed: December 28, 2016
    Publication date: May 4, 2017
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Tsvee LAPIDOT, Alexander KALINKOVICH, Matityahu FRIDKIN
  • Patent number: 9567371
    Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.
    Type: Grant
    Filed: October 11, 2015
    Date of Patent: February 14, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Tsvee Lapidot, Alexander Kalinkovich, Matityahu Fridkin
  • Publication number: 20160324975
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Application
    Filed: July 22, 2016
    Publication date: November 10, 2016
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN, Haim TSUBERY
  • Patent number: 9480751
    Abstract: The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: November 1, 2016
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Yoram Shechter, Matityahu Fridkin
  • Publication number: 20160280739
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: June 12, 2016
    Publication date: September 29, 2016
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Michal SCHWARTZ-EISENBACH, Matityahu FRIDKIN, Michal CARDON-YAAKOV
  • Patent number: 9433683
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: September 6, 2016
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
    Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
  • Patent number: 9382293
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 5, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
  • Publication number: 20160122391
    Abstract: The invention is directed to ?-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer.
    Type: Application
    Filed: October 11, 2015
    Publication date: May 5, 2016
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Tsvee LAPIDOT, Alexander KALINKOVICH, Matityahu FRIDKIN
  • Publication number: 20160000927
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 7, 2016
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN, Haim TSUBERY
  • Patent number: 9155780
    Abstract: The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: October 13, 2015
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Tsvee Lapidot, Alexander Kalinkovich, Matityahu Fridkin
  • Patent number: 9119883
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: September 1, 2015
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
  • Publication number: 20150202310
    Abstract: The present invention provides a long chain fatty acid (LCFA)-like albumin-binding probe/ligand containing no hydrolysable bond and having an enhanced associating affinity with human serum albumin, which upon conjugation with an amino- or mercapto-containing short-lived drug and administration of the conjugate, significantly prolongs the life time of said drug without substantially interfering with its pharmacological activity. The invention further provides conjugates of said probe with amino- or mercapto-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: April 4, 2012
    Publication date: July 23, 2015
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD
    Inventors: Yoram Shechter, Matityahu Fridkin
  • Publication number: 20150093370
    Abstract: The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Inventors: Yoram SHECHTER, Matityahu FRIDKIN
  • Publication number: 20150057219
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Yoram SHECHTER, Matityahu Fridkin, Haim Tsubery
  • Publication number: 20150051151
    Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Michal Eisenbach-Schwartz, Matityahu Fridkin, Michal Cardon-Yaakov
  • Patent number: 8877709
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: November 4, 2014
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
  • Patent number: 8735350
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: May 27, 2014
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery